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Background: Helicobacter pylori neutrophil-activating protein (HP-NAP) is involved in H. pylori-induced gastric
inflammation. Due to its immunogenic and immunomodulatory properties, HP-NAP has been used for developing
vaccines against H. pylori infection and new drugs for cancer therapy.
Results: Here, we provide a simple process for high-yield production of HP-NAP by applying one-step negative
chromatography to purify recombinant HP-NAP expressed in Escherichia coli (E. coli). In our E. coli expression system,
recombinant HP-NAP constitutes nearly 70% of the total protein. Overexpressed recombinant HP-NAP is almost
completely soluble upon cell lysis at pH 9.5. Under the optimal condition at pH 8.0, recombinant HP-NAP with
purity higher than 95% can be obtained from E. coli by collecting the unbound fraction using diethylaminoethyl
(DEAE) Sephadex resin in batch mode. The overall yield of HP-NAP from a 50-ml E. coli culture is ~19 mg. The purified
HP-NAP folds into a multimer with a secondary structure of α-helix and is able to trigger the production of reactive
oxygen species by neutrophils.
Conclusions: Purification of recombinant HP-NAP overexpressed in E. coli using DEAE Sephadex negative mode batch
chromatography is an efficient method for high-yield production of highly pure HP-NAP in its native state. The purified
HP-NAP is useful for various clinical applications including vaccine development, diagnosis, and new drug development.
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Helicobacter pylori (H. pylori) colonizes the gastric mu-
cosa of human stomach for over half of the entire popula-
tion. The majority of the infected people are asymptomatic
with moderate inflammation. However, the infected people
have a 10 to 20% of lifetime risk of developing peptic ulcer,
and ~1% of risk of acquiring gastric cancer [1,2]. H. pylori-
induced chronic active inflammation is characterized by
the infiltration of various inflammatory cells, such as poly-
morphonuclear leukocytes, lymphocytes, monocytes, and
macrophages, at the gastric mucosa [3,4]. Helicobacter
pylori neutrophil-activating protein (HP-NAP), a major* Correspondence: hwfu@life.nthu.edu.tw
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unless otherwise stated.virulence factor of H. pylori, could play a key role in re-
cruitment and activation of these immune cells during H.
pylori infection.
HP-NAP was first identified by its ability to promote
the production of reactive oxygen species (ROS) by neu-
trophils and the adhesion of neutrophil to endothelial
cells [5]. This protein is a spherical dodecamer composed
of identical subunits [6]. Each subunit is a four-α-helix
bundle protein with a molecular weight of approximately
17 kDa [6,7]. HP-NAP released from the bacterium may
cross the stomach epithelial cells and endothelial cells in
the stomach [8-10]. Upon encountering the neutrophils,
HP-NAP directly activates and recruits them to the site of
infection [9,11]. In addition to the induction of ROS pro-
duction, HP-NAP stimulates neutrophils to secrete several
chemokines, including CXCL8/interleukin-8 (IL-8), CCL3/
macrophage inflammatory protein 1 alpha (MIP-1α), and
CCL4/MIP-1β [10], which can recruit and activate additionalhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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duces the secretion of tumor necrosis factor alpha (TNF-α),
IL-6, and IL-8 by monocytes [12,13]. Furthermore, HP-NAP
is a potent immunomodulator to induce a polarized T helper
type 1 (Th1) immune response and to trigger the release of
proinflammatory cytokines, including IL-12, TNF-α, inter-
feron gamma (IFN-γ) [13]. These immune responses in-
duced by HP-NAP may contribute to the pathological
outcome of H. pylori infection.
Despite its pathogenic role, HP-NAP can be used to
develop vaccines against H. pylori and novel therapeutic
agents to treat cancer, as well as allergic and infectious
diseases [11,14]. With regard to vaccine development,
immunization with the multi-protein vaccine containing
HP-NAP, cytotoxin-associated gene A (CagA), and vacuo-
lating cytotoxin A (VacA) in beagle dogs has a therapeutic
effect to induce humoral immune response and reduce
the colonization of bacterium in gastric mucosa [15]. This
protein vaccine has been evaluated for its safety and im-
munogenicity in a clinical trial [16]. HP-NAP has also
been delivered by attenuated viral vectors as a recombin-
ant protective antigen in mice [17]. These findings support
the idea that HP-NAP can be used to develop vaccines for
H. pylori immunoprophylaxis in humans. In the develop-
ment of novel therapeutic agents, recombinant HP-NAP
encoded by attenuated measles viral vectors has a thera-
peutic effect on metastatic breast cancer in mice [18]. Re-
combinant HP-NAP expressed from oncolytic adenovirus
has also been shown to have an antitumor ability against
neuroendocrine tumors in vivo [19]. Furthermore, in a
mouse model of bladder cancer implant, peritumoral injec-
tion of HP-NAP reduced the burden and vascularization of
the tumor [20]. In addition to cancer therapy, administra-
tion of HP-NAP to mice inhibits the Th2 responses in
ovalbumin-induced allergic asthma and Trichinella spira-
lis infection [21,22]. Therefore, HP-NAP is a potent
immunomodulator to trigger Th1-polarized immune re-
sponses for cancer therapy and to down regulate Th2-Figure 1 The effect of pH on the solubility of recombinant HP-NAP upo
ice-cold Tris–HCl buffer at the indicated pH ranging from 7.0 to 9.5. Cells were
(W) were centrifuged to separate soluble fractions (S) and insoluble pellets (I).
are indicated at the side of the gels. B, The percentage of solubility of recomb
the intensity of HP-NAP band on SDS gels for the soluble fraction (S) divi
the mean ± S.D. of at least two experiments.mediated immune responses elicited by allergic reactions
and parasitic infections. Thus, HP-NAP could be used in
clinical therapy.
Several methods for purification of recombinant HP-
NAP expressed in Escherichia coli (E. coli) in its native
state have been reported. In these reported methods, at
least two chromatographic steps, including gel-filtration
chromatography, are required to obtain pure HP-NAP
[23-25]. However, recombinant HP-NAP expressed in
Bacillus subtilis (B. subtilis) has been reported to be
purified by using one-step diethylaminoethyl (DEAE)
anion-exchange chromatography through the collection of
the unbound fraction at pH 8.0 [26]. Due to the low ex-
pression level of HP-NAP in B. subtilis, the overall yield of
recombinant HP-NAP was not satisfactory. In our E. coli
expression system, HP-NAP was highly overexpressed
[25]. Since the endogenous proteins in different expres-
sion systems are different, we re-investigate whether the
same approach can be applied to purify recombinant HP-
NAP expressed in E. coli in one step. By optimization of
the conditions for cell lysis and purification, we herein re-
port a simple method using DEAE Sephadex negative
mode batch chromatography for high yield purification of
recombinant HP-NAP expressed in E. coli.
Results
Effect of pH on solubility of HP-NAP in E. coli lysate
To improve the solubility of HP-NAP during the cell
lysis stage, E. coli expressing recombinant HP-NAP was
lysed in Tris buffer with pH ranging from 7.0 to 9.5. As
shown in Figure 1, overexpressed recombinant HP-NAP
was detected as a major band with an apparent molecu-
lar weight of 17 kDa by SDS-PAGE. At pH 7.0, little
amount of recombinant HP-NAP was present in the sol-
uble fraction (Figure 1). The amount of HP-NAP de-
tected in the soluble fraction was markedly increased at
pH 7.5 to 9.5 (Figure 1). At pH 9.5, HP-NAP was mainly
present in the soluble fraction (Figure 1). This resultn E. coli lysis. A, E. coli BL21(DE3) expressing HP-NAP was suspended in
then disrupted by sonication as described in Methods. Whole cell lysates
The proteins were analyzed by SDS-PAGE. Molecular weights (M) in kDa
inant HP-NAP in the whole cell lysate at each pH was calculated from
ded by that for the whole cell lysate (W). Data were represented as
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at pH 9.5, which is far from the reported pI, 6.75, of HP-
NAP [7].
Optimization of the negative purification of HP-NAP
expressed in E. coli
Our previous study has shown that recombinant HP-
NAP expressed in B. subtilis can be obtained in high
purity by negative purification through the collection of
the unbound fraction using DEAE Sephadex anion-
exchange resin at pH 7.5 and 8.0 [26]. Since the upper
limit of the pH working range for DEAE is 9.0, we here
re-investigated whether the same approach can be used
to isolate highly pure recombinant HP‐NAP expressed
in E. coli over a wider pH range of 7.0 to 9.0. The sol-
uble fraction containing recombinant HP-NAP isolated
from E. coli lysate at pH 9.0 and those adjusted to pH
8.5, 8.0, 7.5, and 7.0 were subjected to purification by
DEAE Sephadex and DEAE Sepharose anion-exchange
resins. At pH 7.5 to 8.5, the majority of the recombinant
HP-NAP remained in the unbound fraction for both
resins (Figure 2A). At pH 8.0, only little amount of re-
combinant HP-NAP was detected in the elution fraction
(Figure 2A). Also, the amount of recombinant HP-NAP
in the elution fraction for DEAE Sepharose resin was
higher than that for DEAE Sephadex resin (Figure 2A),
indicating that DEAE Sepharose resin is capable of bind-
ing more recombinant HP-NAP than DEAE Sephadex
resin. However, at pH 7.0 and 9.0, recombinant HP-NAP
was mainly present in the elution fraction for both resins
(Figure 2A). At all pH values investigated, recombinant
HP-NAP was expressed as an oligomeric protein with an
apparent molecular weight of ~232 kDa by native-PAGE
analysis (Figure 2B). Due to the stronger binding ability
of DEAE Sepharose resin to the recombinant HP-NAP
at pH 8.0, the overall yield of the recombinant HP-NAP
obtained from the unbound fraction using DEAE Seph-
arose resin could be less. Thus, DEAE Sephadex resin
was chosen to purify recombinant HP-NAP expressed in
E. coli through the collection of the unbound fraction at
pH 8.0.
We next determined an optimal loading ratio of the
amount of soluble proteins from E. coli lysate loaded
onto DEAE Sephadex resin at pH 8.0 to obtain a max-
imum yield of highly pure recombinant HP-NAP by col-
lecting the unbound fraction. At the ratios of 0.3 to 1.5
mg of proteins per milliliter of DEAE Sephadex resins
being tested, the purified recombinant HP-NAP was
present in the unbound and wash fractions (Figure 3A
and B). Most of the impure proteins from E. coli were
present in the elution fractions. The amount of impure
proteins in the elution fraction was increased as the ratio
of protein to resin increased (Figure 3C). Even though
the amount of recombinant HP-NAP was increased inthe unbound fraction as the ratio of protein to resin in-
creased (Figure 3A), the amount of recombinant HP-
NAP and impure proteins in the elution fraction was
not markedly increased when the ratio of protein to
resin reached 1.5 mg/ml (Figure 3C). This result sug-
gests that the binding capacity of DEAE Sephadex resin
has reached its maximum level at the ratio of 1.5 mg of
proteins per milliliter resins. Thus, the optimized amount
of proteins loaded onto DEAE Sephadex resin should be
1.5 mg of proteins per milliliter resins for purification of
recombinant HP-NAP expressed in E. coli.
Purification of HP-NAP expressed in E. coli by negative
mode batch chromatography using DEAE Sephadex
anion-exchange resin
Recombinant HP-NAP overexpressed in E. coli was sub-
jected to DEAE Sephadex negative mode batch chroma-
tography at pH 8.0 with the ratio of protein to resin
being 1.5 mg/ml. As shown in Figure 4A, the majority of
recombinant HP-NAP remained in the unbound fraction
and some residual recombinant HP-NAP was present in
the wash fractions. Only little amount of recombinant
HP-NAP was present in the elution fraction as detected
by immunoblotting (Figure 4B). The unbound fraction
and the wash fractions containing recombinant HP-NAP
were pooled. After the pooled fraction was subjected to
dialysis for buffer exchange to Dulbecco’s phosphate-
buffered saline (D-PBS), pH 7.2, and to syringe filtration
for endotoxin removal, the purity of recombinant HP‐
NAP was further increased (Figure 5A and Table 1) and
the amount of endotoxin was less than 2.22 endotoxin
unit (EU)/mg protein. The purified recombinant HP-
NAP was an oligomeric protein with an apparent mo-
lecular weight of ~232 kDa by native-PAGE analysis
(Figure 5B) and was specifically recognized by the
monoclonal antibody against HP-NAP by immunoblot
analysis (Figure 5C). A typical result for purification of
HP-NAP expressed in E. coli is shown in Table 1. The pur-
ity of HP-NAP was 95.97% after the step of DEAE Sepha-
dex chromatography, by which a recovery of 90.5% was
achieved. After dialysis and syringe filtration, the final
yield was 132.4 mg HP-NAP per gram of cell paste from
E. coli culture, and the final purity of HP-NAP achieved
was 99.32% with a total recovery of 82.1%. This result
reveals that negative purification of recombinant HP-
NAP expressed in E. coli using DEAE Sephadex anion-
exchange resin at pH 8.0 is able to obtain recombinant
HP-NAP in one step with high purity and high yield.
Structural and functional characterization of purified
HP-NAP
The structural and molecular properties of the purified re-
combinant HP-NAP were examined by gel filtration, ana-
lytical ultracentrifugation, and circular dichroism (CD)
Figure 2 Purification of recombinant HP-NAP expressed in E. coli by DEAE resins at pH 7.0 to 9.0. Soluble fractions of E. coli expressing
HP-NAP lysed at pH 9.0 were adjusted to the indicated pH ranging from 7.0 to 9.0 and a protein concentration of 0.3 mg/ml. These adjusted
fractions, indicated as load, were then loaded onto DEAE Sephadex and DEAE Sepharose resins to purify recombinant HP-NAP by a batch method
at 4°C as described in Methods. The unbound, wash, and elution fractions were analyzed by SDS-PAGE (A) and native-PAGE (B). Molecular
weights (M) in kDa are indicated on the left of the stained gels. Similar results were obtained in at least two to four independent experiments.
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analysis, recombinant HP-NAP was eluted as a single peak
with the molecular weight of about 150 kDa (Figure 6A),
which is consistent with the previous report [5] but is
much lower than the molecular weight of ~232 kDa as de-
termined by native-PAGE analysis (Figure 2B and 5B) and
the theoretical molecular weight of 203 kDa of dodeca-
meric HP-NAP. The low apparent molecular weight of
HP-NAP determined by gel filtration may be due to a
more compact overall shape of HP-NAP as comparedwith those of the standard proteins used for calibration.
The high apparent molecular weight of HP-NAP deter-
mined by native-PAGE may be resulted from a less
negative net charge of HP-NAP. By analytical ultracentri-
fugation analysis, recombinant HP-NAP was sedimented
as a single peak with a sedimentation coefficient of 9.8 S
(Figure 6B). These findings indicate that recombinant HP-
NAP purified from E. coli is assembled into an oligomeric
protein. Structure analysis from CD spectroscopy showed
that the recombinant HP-NAP was mainly composed of
Figure 3 Optimization of the amount of proteins loaded onto resins for purifying recombinant HP-NAP from E. coli. The soluble proteins
from the whole cell lysate of E. coli BL21(DE3) expressing HP-NAP were loaded onto DEAE Sephadex resins according to the indicated ratio of mg
proteins per milliliter of resins to purify recombinant HP-NAP by a batch method at pH 8.0 as described in Methods. The soluble protein, indicated
as load (L), the unbound fraction (A), wash fraction (B), and elution fraction (C) were analyzed by SDS-PAGE. Molecular weights (M) in kDa are
indicated on the left of the stained gels. Similar results were obtained in two independent experiments.
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NAP obtained by negative purification using DEAE
Sephadex anion-exchange resin retained its oligomeric
status with α-helical structure.
The ability of recombinant HP-NAP purified from E.
coli to induce ROS production by human neutrophils
was examined by 2’,7’-dihydrodichlorofluorescein diacetate
(H2DCFDA)-derived fluorescence and luminol-dependent
chemiluminescence assays. H2DCFDA-derived fluoro-
chrome was used as an indicator of intracellular ROS level
generated by neutrophils. The production of ROS was sig-
nificantly increased by at least 1.3 fold in cells stimulated
with HP-NAP as compared to the control cells (Figure 7).
Luminol-dependent chemiluminescence was used to
measure the generation of both extracellular and intracel-
lular ROS by neutrophils upon HP-NAP stimulation. The
pattern of HP-NAP-induced luminol-dependent chemilu-
minescence is shown in Figure 8A. The stimulation of re-
combinant HP-NAP caused a significant burst respiration
of neutrophils in comparison with the control as indicated
by the increased chemiluminescence signals of both the
area under the curve and the peak value (Figure 8B and C).
Therefore, recombinant HP-NAP purified from E. coli is
capable of activating human neutrophils to produce ROS.Figure 4 Purification of recombinant HP-NAP from E. coli by DEAE Seph
from the whole cell lysate of E. coli BL21(DE3) expressing HP-NAP was subject
Methods. The fractions of wash and elution ranged from 1 to 23 and 24 to 33
selected elution fractions were analyzed by SDS-PAGE (A) and immunoblottin
stained gel and the blot. Data were representative of at least two independenDiscussion
In this study, the effect of pH on negative purification of
recombinant HP-NAP overexpressed in E. coli using
DEAE anion-exchange resins was investigated. At pH
7.0, most of the recombinant HP-NAP bound to DEAE
resins, while at pH ranging from 7.5 to 9.0, most of the
recombinant HP-NAP remained in the unbound frac-
tion. At pH 8.0, the amount of recombinant HP-NAP
present in the unbound fraction reached a maximum
level. Under the optimized condition at pH 8.0, recom-
binant HP-NAP can be obtained in one step with high
purity and high yield by collecting the unbound fraction
from batch chromatography using DEAE Sephadex
anion-exchange resin. The purified recombinant HP-
NAP kept its α-helical oligomeric structure and was cap-
able of stimulating neutrophils to produce ROS.
Recombinant HP-NAP expressed in E. coli purified by
anion-exchange chromatography has been reported to
be present in the flow-through fraction. DEAE Sepharose
resin and Q Sepharose resin were used to purify recom-
binant HP-NAP expressed in E. coli by collecting the
flow-through fraction at pH 7.5 and pH 8.0, respectively
[23,24]. Thus, the ionizable ligands of the resin and the
pH of the buffer may serve as two important parametersadex negative mode batch chromatography. The soluble fraction
ed to DEAE Sephadex anion-exchange chromatography as described in
, respectively. The unbound fraction (U), selected wash fractions, and
g (B). Molecular weights (M) in kDa are indicated on the left of the
t experiments.
Figure 5 PAGE and immunoblotting analysis of the purification process of recombinant HP-NAP expressed in E. coli. The whole cell
lysate (W) and soluble fraction (S) of E. coli BL21(DE3) expressing HP-NAP, the pooled fraction (P) of the unbound fraction and wash fractions
containing HP-NAP from DEAE Sephadex chromatography, the dialyzed HP-NAP solution (D), and the filtrated HP-NAP solution (F) were analyzed
by SDS-PAGE (A), native-PAGE (B), and immunoblotting (C). Molecular weights (M) in kDa are indicated on the left of the stained gels and the
blot. Data were representative of at least three independent experiments.
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rather than binds to the resin. However, both studies show
that an extra gel filtration chromatographic step is
required to achieve higher purity. Our finding that less
HP-NAP bound to DEAE Sephadex resin than DEAE
Sepharose resin indicates that the matrix of the resin also
affects the protein binding. In this study, we first opti-
mized the pH of the buffer to allow the maximum amount
of HP-NAP was present in the unbound fraction. Then,
an appropriate amount of the soluble proteins from E. coli
lysates loaded onto DEAE Sephadex resin at pH 8.0 was
further adjusted to ensure the maximum binding of the
impure proteins from E. coli to the resin so that one-step
negative purification of highly pure recombinant HP-NAP
from E. coli could be achieved.
Our results show that purification of recombinant HP-
NAP with more than 95% purity and 90% recovery was
achieved at the step of DEAE Sephadex chromatography
(Table 1). The yield of HP-NAP from a 50-ml E. coli cul-
ture was 18.9 mg. Since the purity of recombinant HP-
NAP in the E. coli lysate was ~70% (Table 1), such a
high level expression of recombinant HP-NAP in E. coli
should increase the concentration and purity of HP-
NAP in the flow-through fraction, resulting in a highTable 1 Purification summary table of recombinant HP-NAP e








Whole cell lysate 26.70 20.00 69.45 18.54
Supernatant 28.60 20.00 73.34 20.98
DEAE Sephadex chromatography 19.78 59.95 95.97 18.98
Dialysis 18.54 57.95 97.12 18.01
Acrodisc syringe filtration 15.33 56.79 99.32 15.23
aFrom 0.115 g of E.coli cell paste obtained from 50 ml culture.
bProtein concentration determined by the Bradford method with bovine serum alb
cValues determined from densitometry measurement as described in Methods.
dValues determined by multiplying the values in the column of “Total protein” and
eValues determined by dividing the amount of HP-NAP from each purification step
fValues determined by dividing the amount of HP-NAP from each purification steprecovery and high purity of recombinant HP-NAP using
the purification method presented here. In our other re-
ports, even though recombinant HP-NAP was expressed
in the same system, the purity of HP-NAP obtained by
using the two-step gel-filtration chromatography was
98% [25], and the yield of HP-NAP was 91.5 mg per liter
of E. coli culture [27]. There is at least a 4-fold increase
in the yield of recombinant HP-NAP purified from E.
coli using this negative chromatography with DEAE
Sephadex anion-exchange resin as compared to the two-
step gel filtration chromatography. The batch chroma-
tography using DEAE Sephadex anion-exchange resin
also reduces the purification time as compared to the
gel-filtration chromatography. Therefore, DEAE Sepha-
dex negative mode batch chromatography presented in
this study is a simple and efficient method to purify re-
combinant HP-NAP expressed in E. coli.
Conclusions
In this study, a method of negative chromatography
using DEAE Sephadex anion-exchange resin in batch
mode has been established to purify recombinant HP-
NAP expressed in E. coli in one step. After optimization
of the conditions of cell lysis and purification, highlyxpressed in E. coli a
nt of HP-NAP Step recovery of HP-NAP
(%)e







umin (BSA) as the reference.
“Purity”.
by that from the previous step.
by that from the whole cell lysate.
Figure 6 Molecular and structural properties of purified recombinant HP-NAP expressed in E. coli. The apparent molecular weight,
sedimentation coefficient, and secondary structure of HP-NAP in D-PBS, pH 7.2, were analyzed by gel filtration, analytical ultracentrifugation, and
CD spectroscopy, respectively, as described in Methods. A, The UV absorbance was recorded at 280 nm for the elution from a HiLoad 16/60
Superdex 200 prep grade gel gel-filtration column. The molecular weights of the protein markers were indicated at the chromatogram. B, The
sedimentation coefficient distribution c(s) was shown as a function of S. The c(s) distribution was analyzed using the software program SEDFIT.
C, The far UV CD spectrum of HP-NAP was recorded at the wavelength range of 195 to 260 nm. Data were representative of at least three
independent experiments.
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tained in high yield. HP-NAP purified from this ap-
proach should be beneficial for the development of
vaccines, drugs, or diagnostics against H. pylori.
Methods
Expression of recombinant HP-NAP in E. coli
E. coli BL21(DE3) harboring an expression plasmid of
pET42a-NAP encoding a nap gene from H. pylori
strain 26695 [GenBank:AE000543.1, Gene: HP0243]
prepared as previously described [25] was used for pro-
tein expression. The bacteria were streaked on a LB
agar plate containing 50 μg/ml kanamycin, and then
the plate was incubated at 37°C for 16 hr. A singleFigure 7 Production of ROS by neutrophils stimulated with
recombinant HP-NAP determined by H2DCFDA-derived
fluorescence assay. Human neutrophils (1 x 105 cells) were treated
with 0.5 μM HP-NAP and D-PBS, pH 7.2, as a negative control at 37°C.
The content of ROS generated from neutrophils was measured
continuously by using H2DCFDA-derived fluorescence assay as
described in Methods. Data were represented as the mean ± S.D.
of one experiment in triplicate (*, p<0.05). Similar results were obtained
in two independent experiments.colony was picked and inoculated into 5 ml of LB broth
containing 50 μg/ml kanamycin. The preculture was in-
cubated at 37°C for 16 hr with shaking at 170 rpm. A
volume of 3 ml of the above preculture was then inocu-
lated into the 300 ml of LB broth containing 50 μg/ml
kanamycin, and the culture was incubated at 37°C for 2
hr with shaking at 170 rpm until the absorbance at 600
nm reached approximately 0.4-0.5. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added into the cul-
ture to a final concentration of 0.4 mM for induction of
the expression of HP-NAP. The culture was incubated
for 3 hr until the absorbance at 600 nm reached ap-
proximately 1.6 to 1.7. Afterwards, the cells were cen-
trifuged at 6,000 × g at 4°C for 15 min to remove the
supernatant, and the pellet was preserved at −70°C
until purification.
The above E. coli cell pellets from 9 ml of culture
were resuspended in one-third of the culture volume of
20 mM Tris buffer (Tris–HCl, pH 7.0, 7.5, 8.0, 8.5, 9.0,
and 9.5), 50 mM NaCl, and 0.1% (v/v) protease inhibi-
tor mixture (PI mix) at 4°C. The PI mix contained 0.13
M phenylmethylsulfonyl fluoride (PMSF), 0.3 M N-
alpha-tosyl-L-lysinyl-chloromethylketone (TLCK), and
0.3 M N-tosyl-L-phenylalaninyl-chloromethylketone
(TPCK). The bacterial suspensions were disrupted by
an ultrasonic processor SONICS VCX-750 (Sonics &
Materials, Newtown, CT, USA) on ice at 20% amplitude
with 5 sec on and 10 sec off pulses for 4.5 min. The lys-
ate was centrifuged at 30,000 × g at 4°C for 1 hr to sep-
arate insoluble and soluble proteins by using a himac
CS150NX table-top microcentrifuge with a S80AT3
rotor (Hitachi Koki Co. Ltd., Tokyo, Japan). The pro-
teins in whole cell lysates and soluble and insoluble
fractions were examined by SDS-PAGE using gels con-
taining 15% acrylamide.
Figure 8 Production of ROS by neutrophils stimulated with recombinant HP-NAP determined by luminol-dependent chemiluminescence
assay. A, Human neutrophils (1 x 105 cells) were treated with 0.5 μM HP-NAP and D-PBS, pH 7.2, as a negative control at 37°C. The content of ROS
generated from neutrophils was measured continuously by using luminol-dependent chemiluminescence assay as described in Methods. B, The
integral chemiluminescence signals calculated from the area under curve and the peak value of chemiluminescence responses of neutrophils
stimulated with HP-NAP were used to compare with the control. Data were represented as the mean ± S.D. of one experiment in triplicate (*, p<0.05).
Similar results were obtained in two independent experiments.
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at 4°C
The pH value of the soluble fraction from E. coli lysate
in 20 mM Tris–HCl, pH 9.0, and 50 mM NaCl with the
addition of PI mix was kept at pH 9.0 or adjusted to pH
8.5, 8.0, 7.5, and 7.0 with the addition of HCl. The vol-
ume of HCl added to the fraction was according to the
proportion of 40 ml of buffer at pH 9.0 adjusted to pH
8.5, 8.0, 7.5, pH 7.0 at 4°C and was less than 1% of the
fraction volume. In brief, to achieve the desired pH, 1 ml
of soluble fraction at pH 9.0 was added with the follow-
ing: 3.63 ul of 1 N HCl for pH 8.5, 8.88 μl of 1 N HCl
for pH 8.0, 6.44 μl of 2 N HCl for pH 7.5, and 7.31 μl of
2 N HCl for pH 7.0. For keeping the same protein con-
centration in each fraction, these soluble fractions were
then added with 20 mM Tris–HCl and 50 mM NaCl at
their respective pH values to make the total volume
added to each fraction to be 8.88 μl. Protein concentra-
tions were routinely analyzed by the Bradford method
using a commercial dye preparation (Bio‐Rad, Hercules,
CA, USA), and BSA was used as a standard.
Optimization of the purification of recombinant HP-NAP
by DEAE anion-exchange resins
For the experiment to optimize the pH, the soluble frac-
tions from E. coli lysate with a protein concentration of
0.3 mg/ml at pH 9.0 and at the adjusted pH values of
8.5, 8.0, 7.5, and 7.0 were loaded onto DEAE Sephadex
A-25 (Sigma-Aldrich, St. Louis, MO, USA) and DEAE
Sepharose (Amersham Pharmacia Biotech, Uppsala,
Sweden) resins, which were pre-equilibrated with 20
mM Tris–HCl and 50 mM NaCl at the same pH value
of the soluble fractions. For the experiment to optimize
the amount of proteins loaded onto the resins, the sol-
uble fraction in 20 mM Tris–HCl, pH 8.0, and 50 mM
NaCl with a protein concentration of 0.1, 0.2, 0.3, 0.4,and 0.5 mg/ml were loaded onto DEAE Sephadex A-25
and DEAE Sepharose resins, which were pre-equilibrated
with 20 mM Tris–HCl, pH 8.0, and 50 mM NaCl. The
volume ratio of the soluble fraction to the resin was 3:1.
The protein/resin slurries were shaken on a rotator for 30
min at 4°C to ensure the binding of proteins to the resins.
The slurries were centrifuged at 10,000 × g at 4°C for 30
sec, and the supernatant was retained as the unbound
fraction. An equal resin volume of 20 mM Tris–HCl and
50 mM NaCl at the same pH value of the soluble fractions
was added to both DEAE resins, and the slurries were
shaken on a rotator for 10 min to wash out the proteins
nonspecifically binding to the resins. The slurries were
centrifuged at 10,000 × g at 4°C for 30 sec, and the super-
natant was retained as the wash fraction. After washing
five times, an equal resin volume of 20 mM Tris–HCl and
1 M NaCl at the same pH value of the soluble fraction
was added to both DEAE resins, and then the slurries
were shaken on a rotator for 10 min to elute the proteins
binding to the resins. The slurries were centrifuged at
10,000 × g at 4°C for 30 sec, and the supernatant was
retained as the elution fraction. This elution step was re-
peated three times. The fractions including the unbound
fraction, wash fraction, and elution fraction were analyzed
by SDS-PAGE and native-PAGE using gels containing
15% and 10% acrylamide, respectively.
Purification of recombinant HP-NAP expressed in E. coli
by negative mode batch chromatography using DEAE
Sephadex anion-exchange resin
The cell pellet harvested from 50 ml of the culture of E.
coli expressing recombinant HP-NAP was resuspended
in 20 ml of ice-cold 20 mM Tris–HCl, pH 8.0, and 50
mM NaCl with the addition of PI mix. The bacterial sus-
pension was disrupted by a EmulsiFlex-C3 high pressure
homogenizer (Avestin Inc., Ottawa, Canada) at 17,000
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30,000 × g at 4°C for 1 hr to separate soluble proteins
and insoluble debris. The soluble protein fraction with
a protein concentration of 0.5 mg/ml was incubated
with 7 ml of DEAE Sephadex A-25 resin, and protein/
resin slurries were mixed by shaking on a rotator at 4°C
for 1 hr. The volume ratio of the soluble protein frac-
tion to the resin was 3:1. The slurries were then placed
into a column, and the column was run by gravity flow
at 4°C. The solution that flowed through the column
was collected as the unbound fraction. The column was
washed with five resin volumes of 20 mM Tris–HCl,
pH 8.0, and 50 mM NaCl. The volume of each collected
wash fraction was 1 ml for the first resin volume and
1.75 ml for the rest. The proteins binding to the resins
were eluted by the addition of three resin volumes of
20 mM Tris–HCl, pH 8.0, and 1 M NaCl, and the
elutes were collected in 2-ml fractions. The fractions of
unbound, wash, and elution were analyzed by SDS-
PAGE and immunoblotting.
For obtaining a maximum amount of the recombinant
HP-NAP, the wash fractions with protein concentration
of at least 0.1 mg/ml were pooled together with the un-
bound fraction. The pooled fraction containing purified
recombinant HP-NAP was dialyzed against D-PBS, pH
7.2, with 100-fold volume of the pooled fraction for 4 hr
at 4°C by using Spectrum/Por dialysis tubing with mo-
lecular weight cutoff of 14 kDa (Spectrum Laboratories,
Rancho Dominguez, CA, USA) and dialyzed again over-
night with the fresh buffer. After dialysis, the purified re-
combinant HP-NAP was subjected to endotoxin removal
by filtering through a syringe with a positively-charged,
hydrophilic Mustang E membrane at a flow rate ranging
from 2.5 to 4 ml/min. The amount of endotoxin present
in recombinant HP-NAP was less than 2.22 EU/mg
protein as determined by Super Laboratory Company
(Taipei, Taiwan) using an enzyme-linked immunosorbent
assay (ELISA) with the detection limit of 0.005 to 2 EU/
ml. In addition to SDS-PAGE, purified recombinant HP-
NAP was routinely analyzed by gel filtration chromatog-
raphy and native-PAGE as described previously [26] to
confirm its oligomeric properties. The percentage purity
of HP-NAP was calculated from the intensities of pro-
tein bands on SDS gels as follows: purity (%) = (intensity
of HP-NAP)/(intensity of total proteins) × 100. The
intensities of protein bands were quantified by densitom-
etry analysis using multi gauge software V3.0 (Fujifilm,
Tokyo, Japan).
Immunoblotting
The protein samples were separated by a 15% SDS-
PAGE gel and then transferred onto a polyvinylidene
difluoride (PVDF) membrane. The membrane was incu-
bated in 5% nonfat milk in Tris-buffered saline/Tween-20 (TBST) containing 50 mM Tris‐HCl, pH 7.4, 15 mM
NaCl, and 0.1% Tween‐20 at room temperature for 1 hr
to block nonspecific binding. The membrane was then
probed with hybridoma culture supernatants containing
mouse monoclonal antibody MAb 16F4 against HP-
NAP [17] with a dilution factor of 1:200 in TBST con-
taining 5% BSA at 4°C overnight. After three washes
with TBST containing 5% nonfat milk for 10 min each,
the membrane was probed with horseradish peroxidase-
conjugated mouse secondary antibody (Jackson Immu-
noResearch, West Grove, PA, USA) at a dilution of
1:5000 in TBST containing 5% nonfat milk at room
temperature for 1 hr and then washed with TBST three
times. The signals on the immunoblot were detected by
the enhanced chemiluminescence assay (ECL) Western
blotting detection reagents (PerkinElmer, Waltham, MA,
USA) and LAS-3000 imaging system (Fujifilm, Tokyo,
Japan).
Analytical ultracentrifugation
The sedimentation coefficient of HP-NAP in D-PBS, pH
7.2, was determined by analytical ultracentrifugation
with a PorteomeLab™ XL-I protein characterization sys-
tem (Beckman Coulter, Brea, CA, USA) at 116,444 × g
(38,000 rpm) at 20°C for 240 min as previously described
[26]. Sedimentation coefficient distribution, c(s), of HP-
NAP was analyzed with the software program SEDFIT.
Circular dichroism spectroscopy
The secondary structure of recombinant HP-NAP in D-
PBS, pH 7.2, was measured by CD spectroscopy in the
far UV region. The CD spectrum was recorded on an
Aviv model 62A DS CD spectrophotometer (Aviv Bio-
medical, Lakewood, NJ, USA) at 25°C with a 1 mm path‐
length quartz cuvette. A concentration of 0.3 mg/ml of
HP-NAP was repetitively scanned from 260 to 195 nm
in 1 nm increments. A 1 nm bandwidth and 1 sec aver-
aging time were utilized. The blank-subtracted CD sig-
nals from a total of five scans were averaged. The mean
residue ellipticity (MRE) was calculated from the for-
mula: MRE= θ/(10 × L × C × N), where θ is the CD sig-
nal (mdeg), L is the path length of the cell (cm), C is the
protein concentration of the sample (M), and N is the
number of peptide bonds.
Isolation of human neutrophils
Human peripheral blood was collected in a tube with so-
dium heparin by venipuncture from three healthy adult
volunteers, who signed informed consents under the ap-
proval of the Institutional Review Board (IRB) of National
Tsing-Hua University, Hsinchu, Taiwan. Neutrophils were
isolated from heparinized blood by dextran sedimenta-
tion of erythrocytes, followed by Ficoll-Paque PLUS
density gradient (GE Healthcare, Buckinghamshire, UK)
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pellet containing neutrophils was resuspended in D-
PBS, pH 7.2, containing 5 mM glucose (D-PBS-G). The
cells were kept on ice and used within 5 hr. The viabil-
ity of neutrophils was assessed by trypan blue dye ex-
clusion count using a hemocytometer. The purity of
neutrophils was determined by examination of at least
700 cells on each Liu’s stained cytocentrifuged slide
using Zeiss Axiovert 200 microscope with 400× magni-
fication (Carl Zeiss, Jena, Germany). The viability and
purity of neutrophils in each preparation exceeded
96.1% and 95.3%, respectively.
Measurement of reactive oxygen species
The production of ROS from human neutrophils mea-
sured by H2DCFDA-derived fluorescence microplate
assay was essentially the same as previously described
[26]. Briefly, aliquots of 50 μl of isolated human neutro-
phils at 2 × 106 cells/ml in D‐PBS‐G were dispensed into
individual wells of a 96‐well black plate (Nunc, Rochester,
NY, USA) with a flat bottom. Subsequently, 150 μl of the
mixture containing 0.9 mM CaCl2, 0.5 mM MgCl2, 0.27
mM H2DCFDA (Invitrogen, Carlsbad, CA, USA), and
0.67 μM HP-NAP in the D‐PBS, pH 7.2, was added into
each well to a final volume of 200 μl. The cells were then
incubated at 37°C. H2DCFDA was dissolved in methanol
at a concentration of 10 mM as the stock solution and di-
luted into D-PBS, pH 7.2, containing 0.9 mM CaCl2 and
0.5 mM MgCl2 immediately before use. The final concen-
trations of H2DCFDA and recombinant HP-NAP were 0.2
mM and 0.5 μM, respectively. The emission of fluores-
cence at 538 nm was monitored at 37°C with excitation at
485 nm in triplicate every 30 min for 2 hr using a Wallac
1420–012 VICTOR 3 multilabel counter (Perkin-Elmer,
Waltham, MA, USA). A rise in the intracellular ROS level
was evaluated by the increase in the DCF fluorescence
intensity calculated from the formula: ΔF= Ft – F0, where
Ft and F0 represent the fluorescence intensity at time t
and time 0 after incubation, respectively.
The production of ROS from human neutrophils mea-
sured by luminol-dependent chemiluminescence assay
was as previously described [25] except for the addition
of calcium and magnesium in the assay buffer. Briefly,
aliquots of 50 μl of isolated human neutrophils at 2 ×
106 cells/ml in D-PBS-G were dispensed into individual
wells of a 96-well white plate (Nunc, Rochester, NY,
USA) with a flat bottom. Subsequently, 150 μl of the
mixture containing 0.9 mM CaCl2, 0.5 mM MgCl2, 13.3
μM luminol (sigma), and 0.67 μM HP-NAP in the D‐
PBS, pH 7.2, was added into each well to a final volume
of 200 μl. The cells were then incubated at 37°C. Lumi-
nol was dissolved in dimethyl sulfoxide (DMSO) at a
concentration of 10 mM as the stock solution and di-
luted into D-PBS, pH 7.2, containing 0.9 mM CaCl2 and0.5 mM MgCl2 immediately before use. The final con-
centrations of luminol and recombinant HP-NAP were
10 μM and 0.5 μM, respectively. The emission of chemi-
luminescence was monitored in triplicate for 5 sec per
well over a 3-hr period by a Wallac 1420 (Victor2) Mul-
tilabel Counter (Perkin-Elmer, Waltham, MA, USA).
Statistical analysis
Results were expressed as mean ± standard deviation (S.
D.). Statistical analysis was performed by using Excel
2010 software (Microsoft). Statistical difference was de-
termined by two-tailed unpaired Student’s t-test. A prob-
ability (p) value which was less than 0.05 was considered
statistically significant.
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